U.S., Feb. 3 -- ClinicalTrials.gov registry received information related to the study (NCT07380386) titled 'SKB105 for Injection in Advanced Solid Tumors' on Jan. 21.
Brief Summary: This is a Phase 1/2 clinical study to evaluate the safety and efficacy of SKB105 in participants with advanced solid tumors. The study includes a dose escalation stage, a dose expansion stage, and a indication expansion stage.
Study Start Date: April 01
Study Type: INTERVENTIONAL
Condition:
Advanced Solid Tumors
Intervention:
DRUG: SKB105 for injection Monotherapy
SKB105 for injection monotherapy, iv drip, every 3 weeks (Q3W), until radiographic disease progression (PD), intolerable toxicity, death, or discontinuation of treatment, whichever occurs first...